BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 6/14/19 $15.0 NA $5.7 NA Seres Therapeutics Inc. (NASDAQ:MCRB) 6/13/19 $60.0 $152.5 $218.2 43% Navidea Biopharmaceuticals Inc....
BioCentury | Aug 16, 2018
Company News

Management tracks: Achillion, Navidea

...managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc....
...become CEO of the immunotherapy company's Macrophage Therapeutics Inc. subsidiary. During a conference call Thursday, Navidea...
...pipeline and addressing its long-term funding needs. CFO and COO Jed Latkin will serve as Navidea's...
BioCentury | Apr 20, 2018
Company News

Cerveau subsidiary gets rights to Navidea's AD imaging agent

...were not disclosed. Navidea obtained exclusive, worldwide rights to NAV4694 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Navidea Biopharmaceuticals Inc....
...Tel Aviv:NAVB), Dublin, Ohio Cerveau Technologies Inc., Boston, Mass. Business: Diagnostic Allison Johnson NAV4694, azd4694 AstraZeneca plc Cerveau Technologies Inc. Navidea Biopharmaceuticals Inc....
BioCentury | Dec 2, 2016
Company News

Navidea, Cardinal Health deal

...Norgine B.V. (Amsterdam, the Netherlands) has exclusive commercialization rights (see BioCentury, March 9, 2015 ). Navidea Biopharmaceuticals Inc....
...NYSE-M:NAVB; Tel Aviv:NAVB), Dublin, Ohio Cardinal Health Inc. (NYSE:CAH), Dublin, Ohio Business: Diagnostic Alex Himes Lymphoseek Cardinal Health Inc. Navidea Biopharmaceuticals Inc. Mannose...
BioCentury | Sep 27, 2016
Company News

Management tracks

...was EVP of business operations and general counsel at Tokai Pharmaceuticals Inc. (NASDAQ:TKAI). Diagnostic play Navidea Biopharmaceuticals Inc....
BioCentury | Feb 22, 2016
Clinical News

Lymphoseek tilmanocept: Phase II started

...of the oral cavity, breast cancer or melanoma. It is also approved in the EU. Navidea Biopharmaceuticals Inc....
BioCentury | Jun 29, 2015
Company News

Bind Therapeutics, Navidea deal

...Bind partnered non-exclusively with Navidea’s Macrophage Therapeutics subsidiary to develop tumor therapies that combine Bind’s Accurin...
...of disease mediated by MBR-positive macrophages and tumor-associated macrophages. Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Navidea Biopharmaceuticals Inc....
BioCentury | Jun 8, 2015
Company News

Alseres, Navidea deal

...Navidea will be eligible to receive a milestone payment upon FDA approval plus royalties. Navidea...
...detection of Parkinson’s disease (see BioCentury, Aug. 6, 2012). Alseres Pharmaceuticals Inc. (OTCQB:ALSE), Auburndale, Mass. Navidea Biopharmaceuticals Inc....
BioCentury | May 18, 2015
Financial News

Navidea completes debt financing

...Ohio Business: Diagnostic Date completed: 2015-05-11 Type: Debt financing Raised: $50 million Investor: CRG Note: Navidea...
BioCentury | May 14, 2015
Financial News

Navidea takes $60M loan

...loan of up to $60 million from CRG, including an initial $50 million at closing. Navidea...
...for the first four years, and a 14% annual interest rate. WBB Securities LLC was Navidea's...
Items per page:
1 - 10 of 271
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...A) 6/14/19 $15.0 NA $5.7 NA Seres Therapeutics Inc. (NASDAQ:MCRB) 6/13/19 $60.0 $152.5 $218.2 43% Navidea Biopharmaceuticals Inc....
BioCentury | Aug 16, 2018
Company News

Management tracks: Achillion, Navidea

...managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc....
...become CEO of the immunotherapy company's Macrophage Therapeutics Inc. subsidiary. During a conference call Thursday, Navidea...
...pipeline and addressing its long-term funding needs. CFO and COO Jed Latkin will serve as Navidea's...
BioCentury | Apr 20, 2018
Company News

Cerveau subsidiary gets rights to Navidea's AD imaging agent

...were not disclosed. Navidea obtained exclusive, worldwide rights to NAV4694 from AstraZeneca plc (LSE:AZN; NYSE:AZN). Navidea Biopharmaceuticals Inc....
...Tel Aviv:NAVB), Dublin, Ohio Cerveau Technologies Inc., Boston, Mass. Business: Diagnostic Allison Johnson NAV4694, azd4694 AstraZeneca plc Cerveau Technologies Inc. Navidea Biopharmaceuticals Inc....
BioCentury | Dec 2, 2016
Company News

Navidea, Cardinal Health deal

...Norgine B.V. (Amsterdam, the Netherlands) has exclusive commercialization rights (see BioCentury, March 9, 2015 ). Navidea Biopharmaceuticals Inc....
...NYSE-M:NAVB; Tel Aviv:NAVB), Dublin, Ohio Cardinal Health Inc. (NYSE:CAH), Dublin, Ohio Business: Diagnostic Alex Himes Lymphoseek Cardinal Health Inc. Navidea Biopharmaceuticals Inc. Mannose...
BioCentury | Sep 27, 2016
Company News

Management tracks

...was EVP of business operations and general counsel at Tokai Pharmaceuticals Inc. (NASDAQ:TKAI). Diagnostic play Navidea Biopharmaceuticals Inc....
BioCentury | Feb 22, 2016
Clinical News

Lymphoseek tilmanocept: Phase II started

...of the oral cavity, breast cancer or melanoma. It is also approved in the EU. Navidea Biopharmaceuticals Inc....
BioCentury | Jun 29, 2015
Company News

Bind Therapeutics, Navidea deal

...Bind partnered non-exclusively with Navidea’s Macrophage Therapeutics subsidiary to develop tumor therapies that combine Bind’s Accurin...
...of disease mediated by MBR-positive macrophages and tumor-associated macrophages. Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Navidea Biopharmaceuticals Inc....
BioCentury | Jun 8, 2015
Company News

Alseres, Navidea deal

...Navidea will be eligible to receive a milestone payment upon FDA approval plus royalties. Navidea...
...detection of Parkinson’s disease (see BioCentury, Aug. 6, 2012). Alseres Pharmaceuticals Inc. (OTCQB:ALSE), Auburndale, Mass. Navidea Biopharmaceuticals Inc....
BioCentury | May 18, 2015
Financial News

Navidea completes debt financing

...Ohio Business: Diagnostic Date completed: 2015-05-11 Type: Debt financing Raised: $50 million Investor: CRG Note: Navidea...
BioCentury | May 14, 2015
Financial News

Navidea takes $60M loan

...loan of up to $60 million from CRG, including an initial $50 million at closing. Navidea...
...for the first four years, and a 14% annual interest rate. WBB Securities LLC was Navidea's...
Items per page:
1 - 10 of 271